Covered recipient · General Payments record
MATTHEW A LUNNING
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$146,366.79
86 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $95,399.50 | 27 |
| Honoraria | $30,915.00 | 6 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,545.00 | 5 |
| Travel and Lodging | $4,940.74 | 16 |
| Food and Beverage | $2,566.55 | 32 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $33,648.10 | 8 |
| E.R. Squibb & Sons, L.L.C. | $23,149.50 | 9 |
| Gilead Sciences, Inc. | $19,346.36 | 3 |
| Genentech USA, Inc. | $18,063.84 | 7 |
| ABBVIE INC. | $15,659.91 | 13 |
| Acrotech Biopharma Inc. | $14,795.95 | 16 |
| Kite Pharma, Inc. | $4,421.73 | 4 |
| RECORDATI_RARE_DISEASES_INC. | $3,740.00 | 3 |
| Eli Lilly and Company | $3,600.00 | 1 |
| Ipsen Biopharmaceuticals, Inc | $3,480.00 | 1 |
| AstraZeneca Pharmaceuticals LP | $2,055.00 | 1 |
| ADC Therapeutics America, Inc. | $1,717.92 | 5 |
| BTG International, Inc. | $1,067.63 | 2 |
| Celgene Corporation | $710.75 | 7 |
| Janssen Global Services, LLC | $675.00 | 1 |
| BeiGene USA, Inc. | $135.74 | 2 |
| Incyte Corporation | $64.29 | 2 |
| Stemline Therapeutics Inc. | $35.07 | 1 |
Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MATTHEW A LUNNING
NPI 1003935081 · CMS profile ID 45615
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
OMAHA, NE
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1003935081?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MATTHEW A LUNNING, NPI 1003935081, CMS profile ID 45615. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003935081?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). MATTHEW A LUNNING, NPI 1003935081, CMS profile ID 45615. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003935081?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- MATTHEW A LUNNING, NPI 1003935081, CMS profile ID 45615, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1003935081?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
86 matching records · $146,366.79 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–86 of 86.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $2,055.00 | 08/01/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104236497 | CMS |
| BTG International, Inc. | $1,000.00 | 08/01/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1126178934 | CMS |
| BTG International, Inc. | $67.63 | 07/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1126178932 | CMS |
| PFIZER INC. | $2,160.00 | 07/25/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131358510 | CMS |
| Incyte Corporation | $27.27 | 07/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141238141 | CMS |
| Celgene Corporation | $135.00 | 07/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101087879 | CMS |
| Celgene Corporation | $51.19 | 07/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101087881 | CMS |
| Celgene Corporation | $61.99 | 07/15/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101087887 | CMS |
| Genentech USA, Inc. | $2,660.00 | 07/08/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133066028 | CMS |
| RECORDATI_RARE_DISEASES_INC. | $1,360.00 | 06/11/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139164414 | CMS |
| Genentech USA, Inc. | $4,940.00 | 06/05/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1133066012 | CMS |
| E.R. Squibb & Sons, L.L.C. | $444.75 | 05/17/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101241220 | CMS |
| ABBVIE INC. | $550.00 | 04/30/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104912427 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,372.00 | 04/26/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101241214 | CMS |
| PFIZER INC. | $15,050.00 | 04/24/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131472534 | CMS |
| RECORDATI_RARE_DISEASES_INC. | $1,020.00 | 04/24/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139164412 | CMS |
| RECORDATI_RARE_DISEASES_INC. | $1,360.00 | 04/17/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139164410 | CMS |
| ABBVIE INC. | $1,100.00 | 04/10/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104912425 | CMS |
| Celgene Corporation | $299.96 | 04/03/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101087865 | CMS |
| ABBVIE INC. | $1,100.00 | 03/05/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104912423 | CMS |
| E.R. Squibb & Sons, L.L.C. | $1,779.00 | 03/04/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101241200 | CMS |
| Eli Lilly and Company | $3,600.00 | 02/23/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1135182787 | CMS |
| PFIZER INC. | $120.28 | 02/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131282572 | CMS |
| ABBVIE INC. | $5,500.00 | 02/19/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104912421 | CMS |
| Janssen Global Services, LLC | $675.00 | 02/15/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1077591929 | CMS |
| ADC Therapeutics America, Inc. | $39.56 | 02/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121185544 | CMS |
| ABBVIE INC. | $37.93 | 02/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104912415 | CMS |
| ABBVIE INC. | $81.80 | 02/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104912417 | CMS |
| ABBVIE INC. | $85.26 | 02/01/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104912419 | CMS |
| ABBVIE INC. | $113.04 | 01/31/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104912407 | CMS |
| ABBVIE INC. | $247.47 | 01/31/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104912409 | CMS |
| ABBVIE INC. | $165.09 | 01/31/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104912411 | CMS |
| ABBVIE INC. | $79.32 | 01/31/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104912413 | CMS |
| E.R. Squibb & Sons, L.L.C. | $444.75 | 01/11/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101241196 | CMS |
| PFIZER INC. | $10,500.00 | 01/11/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1131472538 | CMS |
| ABBVIE INC. | $6,050.00 | 01/08/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104912405 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,231.83 | 3 |
| PY2025 | Principal investigator | $599,062.07 | 14 |
| PY2024 | Principal investigator | $98,348.43 | 13 |
| PY2023 | Principal investigator | $357,492.68 | 18 |
| PY2022 | Principal investigator | $549,677.35 | 28 |
| PY2021 | Principal investigator | $366,268.92 | 13 |
| PY2020 | Principal investigator | $700,094.42 | 17 |
| PY2019 | Recipient | $3,298.00 | 1 |
| PY2019 | Principal investigator | $2,189,582.76 | 17 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
17 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity UNEHEALTH | A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies | No dispute reported | 06/30/2026 | 1202533205 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $205.00 | 11/05/2025 | Non-covered Recipient Entity Unehealth | Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release | No dispute reported | 06/30/2026 | 1235992759 |
| Principal investigator 1 | ABBVIE INC. | $7,840.64 | 10/22/2025 | Non-covered Recipient Entity UNEHEALTH | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202518181 |
| Principal investigator 1 | Kite Pharma, Inc. | $4,066.00 | 10/14/2025 | Non-covered Recipient Entity UNEHEALTH | Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel | No dispute reported | 06/30/2026 | 1212071125 |
| Principal investigator 1 | Kite Pharma, Inc. | $14,208.00 | 10/14/2025 | Non-covered Recipient Entity UNEHEALTH | Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel | No dispute reported | 06/30/2026 | 1212071129 |
| Principal investigator 1 | Eli Lilly and Company | $19,678.00 | 10/09/2025 | Non-covered Recipient Entity UNEHEALTH | LONG-TERM SAFETY OF PIRTOBRUTINIB IN PARTICIPANTS FROM STUDY LOXO-BTK-18001 WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA OR NON-HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1187891636 |
| Principal investigator 1 | Celgene Corporation | $2,766.95 | 10/08/2025 | Non-covered Recipient Entity Unehealth | Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release | No dispute reported | 06/30/2026 | 1222307227 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $468.41 | 08/25/2025 | Covered Recipient Physician | AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1184119833 |
| Principal investigator 1 | Kite Pharma, Inc. | $2,560.00 | 07/22/2025 | Non-covered Recipient Entity UNEHEALTH | Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel | No dispute reported | 06/30/2026 | 1212071121 |
| Principal investigator 1 | Celgene Corporation | $176,317.68 | 06/18/2025 | Non-covered Recipient Entity Unehealth | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) | No dispute reported | 06/30/2026 | 1222306799 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $331,845.36 | 06/18/2025 | Non-covered Recipient Entity Unehealth | Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) | No dispute reported | 06/30/2026 | 1235992757 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $495.21 | 06/01/2025 | Covered Recipient Physician | AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1184119831 |
| Principal investigator 1 | Kite Pharma, Inc. | $1,500.00 | 04/01/2025 | Non-covered Recipient Entity UNEHEALTH | Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel | No dispute reported | 06/30/2026 | 1212071116 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $268.21 | 03/25/2025 | Covered Recipient Physician | AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1184119829 |
| Principal investigator 1 | Kite Pharma, Inc. | $14,208.00 | 02/04/2025 | Non-covered Recipient Entity UNEHEALTH | Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel | No dispute reported | 06/30/2026 | 1212071112 |
| Principal investigator 1 | Celgene Corporation | $10,997.00 | 01/17/2025 | Non-covered Recipient Entity Unehealth | Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells. A prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. | No dispute reported | 06/30/2026 | 1222306865 |
| Principal investigator 1 | ABBVIE INC. | $12,269.44 | 01/08/2025 | Covered Recipient Teaching Hospital UT MD ANDERSON CANCER CENTER | A Study to Assess the Adverse Events Change in Disease Activity and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Follicular Lymphoma (FL) or Chronic Lymphocytic Leukemia (CLL) | No dispute reported | 06/30/2026 | 1202429227 |